Aligos Therapeutics Inc. (ALGS) Misses Q1 EPS by 221c

Aligos Therapeutics Inc. (NASDAQ: ALGS) reported Q1 EPS of ($2.21). Revenue for the quarter came in at $2.83 million.

For earnings history and earnings-related data on Aligos Therapeutics Inc. (ALGS) click here.

You May Also Be Interested In

• Argus Upgrades Moderna (MRNA) to Buy
• MaxLinear (MXL) Reiterated at Buy by Stifel After Fireside Chat With CFO
• What could trigger a Fed rate hike?